메뉴 건너뛰기




Volumn 123, Issue 5, 2010, Pages 454-461

Long-term TNF-α Blockade in Patients with Amyloid A Amyloidosis Complicating Rheumatic Diseases

Author keywords

Amyloid A amyloidosis; Anti tumor necrosis factor alpha blockade; Effectiveness; Immune mediated inflammatory diseases; Infections

Indexed keywords

ADALIMUMAB; AMYLOID A PROTEIN; CHLORAMBUCIL; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

EID: 77950625504     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.11.010     Document Type: Article
Times cited : (43)

References (15)
  • 1
    • 34248185611 scopus 로고    scopus 로고
    • Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis
    • Jacobsson L.T., Turesson C., Nilsson J.A., et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 66 (2007) 670-675
    • (2007) Ann Rheum Dis , vol.66 , pp. 670-675
    • Jacobsson, L.T.1    Turesson, C.2    Nilsson, J.A.3
  • 2
    • 34347251548 scopus 로고    scopus 로고
    • All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists
    • Carmona L., Descalzo M.A., Perez-Pampin E., et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 66 (2007) 880-885
    • (2007) Ann Rheum Dis , vol.66 , pp. 880-885
    • Carmona, L.1    Descalzo, M.A.2    Perez-Pampin, E.3
  • 3
    • 0037666987 scopus 로고    scopus 로고
    • Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy
    • Gottenberg J.E., Merle-Vincent F., Bentaberry F., et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 48 (2003) 2019-2024
    • (2003) Arthritis Rheum , vol.48 , pp. 2019-2024
    • Gottenberg, J.E.1    Merle-Vincent, F.2    Bentaberry, F.3
  • 4
    • 20944451093 scopus 로고    scopus 로고
    • Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists
    • Fernández-Nebro A., Tomero E., Ortiz-Santamaría V., et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med 118 (2005) 552-556
    • (2005) Am J Med , vol.118 , pp. 552-556
    • Fernández-Nebro, A.1    Tomero, E.2    Ortiz-Santamaría, V.3
  • 5
    • 77950623828 scopus 로고    scopus 로고
    • BIOBADASER: Spanish registry of adverse events of biological therapies in rheumatic diseases
    • Committee B.S. BIOBADASER: Spanish registry of adverse events of biological therapies in rheumatic diseases. Rev Esp Reumatol 29 (2002) 7
    • (2002) Rev Esp Reumatol , vol.29 , pp. 7
    • Committee, B.S.1
  • 6
    • 34250003794 scopus 로고    scopus 로고
    • Natural history and outcome in systemic AA amyloidosis
    • Lachmann H.J., Goodman H.J., Gilbertson J.A., et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356 (2007) 2361-2371
    • (2007) N Engl J Med , vol.356 , pp. 2361-2371
    • Lachmann, H.J.1    Goodman, H.J.2    Gilbertson, J.A.3
  • 7
    • 0033567210 scopus 로고    scopus 로고
    • Invited commentary: propensity scores
    • Joffe M.M., and Rosenbaum P.R. Invited commentary: propensity scores. Am J Epidemiol 150 (1999) 327-333
    • (1999) Am J Epidemiol , vol.150 , pp. 327-333
    • Joffe, M.M.1    Rosenbaum, P.R.2
  • 8
    • 0041653315 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report
    • Gomez-Reino J.J., Carmona L., Valverde V.R., et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48 (2003) 2122-2127
    • (2003) Arthritis Rheum , vol.48 , pp. 2122-2127
    • Gomez-Reino, J.J.1    Carmona, L.2    Valverde, V.R.3
  • 9
    • 23244448608 scopus 로고    scopus 로고
    • Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004
    • Gertz M.A., Comenzo R., Falk R.H., et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 79 (2005) 319-328
    • (2005) Am J Hematol , vol.79 , pp. 319-328
    • Gertz, M.A.1    Comenzo, R.2    Falk, R.H.3
  • 10
    • 34648846150 scopus 로고    scopus 로고
    • Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis
    • Nakamura T., Higashi S., Tomoda K., et al. Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Exp Rheumatol 25 (2007) 518-522
    • (2007) Clin Exp Rheumatol , vol.25 , pp. 518-522
    • Nakamura, T.1    Higashi, S.2    Tomoda, K.3
  • 11
    • 0033895284 scopus 로고    scopus 로고
    • Presentation, survival and prognostic markers in AA amyloidosis
    • Joss N., McLaughlin K., Simpson K., and Boulton-Jones J.M. Presentation, survival and prognostic markers in AA amyloidosis. QJM 93 (2000) 535-542
    • (2000) QJM , vol.93 , pp. 535-542
    • Joss, N.1    McLaughlin, K.2    Simpson, K.3    Boulton-Jones, J.M.4
  • 12
    • 0036401462 scopus 로고    scopus 로고
    • Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis
    • Reyners A.K., Hazenberg B.P., Reitsma W.D., and Smit A.J. Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis. Eur Heart J 23 (2002) 157-161
    • (2002) Eur Heart J , vol.23 , pp. 157-161
    • Reyners, A.K.1    Hazenberg, B.P.2    Reitsma, W.D.3    Smit, A.J.4
  • 13
    • 0025936525 scopus 로고
    • Secondary systemic amyloidosis: response and survival in 64 patients
    • Gertz M.A., and Kyle R.A. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore) 70 (1991) 246-256
    • (1991) Medicine (Baltimore) , vol.70 , pp. 246-256
    • Gertz, M.A.1    Kyle, R.A.2
  • 14
    • 0021972235 scopus 로고
    • Ten years' experience of an amyloid clinic-a clinicopathological survey
    • Browning M.J., Banks R.A., Tribe C.R., et al. Ten years' experience of an amyloid clinic-a clinicopathological survey. Q J Med 54 (1985) 213-227
    • (1985) Q J Med , vol.54 , pp. 213-227
    • Browning, M.J.1    Banks, R.A.2    Tribe, C.R.3
  • 15
    • 0015548572 scopus 로고
    • Renal amyloidosis-a fourteen-year follow-up
    • Triger D.R., and Joekes A.M. Renal amyloidosis-a fourteen-year follow-up. Q J Med 42 (1973) 15-40
    • (1973) Q J Med , vol.42 , pp. 15-40
    • Triger, D.R.1    Joekes, A.M.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.